Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 1, 2013, Pages 73-80

  Barney, Brandon M ^a   Markovic, Svetomir N ^a   Laack, Nadia N ^a   Miller, Robert C ^a   Sarkaria, Jann N ^a   Macdonald, O Kenneth ^b   Bauer, Heather J ^a   Olivier, Kenneth R ^a  

^a MAYO CLINIC   (United States)

^b Therapeutic Radiologists Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EVENTS; BOWEL TOXICITY; COMMON TERMINOLOGY CRITERIA; LOCAL THERAPY; METHODS AND MATERIALS; STEREOTACTIC BODY RADIATION THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

PATIENT MONITORING;

RADIOTHERAPY;

BEVACIZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DIGESTIVE SYSTEM INJURY; DISEASE DURATION; DUODENUM PERFORATION; DUODENUM ULCER; FEMALE; HUMAN; INCIDENCE; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; SEPSIS; STEREOTACTIC BODY RADIATION THERAPY; STOMACH PERFORATION; STOMACH ULCER; TREATMENT DURATION;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL, HUMANIZED; DUODENAL DISEASES; HUMANS; INDOLES; INTESTINAL DISEASES; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIMIDINES; PYRROLES; RADIOSURGERY; RADIOTHERAPY DOSAGE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; STOMACH ULCER; SULFONAMIDES; ULCER;

EID: 84881346489     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.05.012     Document Type: Article

References (38)

1. N. Ferrara, K.J. Hillan, and W. Novotny Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 2005 328 335
2. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
3. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
4. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
5. M. Reck, J. von Pawel, and P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 2009 1227 1234
6. R. Timmerman, R. Paulus, and J. Galvin Stereotactic body radiation therapy for inoperable early stage lung cancer JAMA 303 2010 1070 1076
7. K.E. Rusthoven, B.D. Kavanagh, and H. Cardenes Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases J Clin Oncol 27 2009 1572 1578
8. N. Kopek, M.I. Holt, and A.T. Hansen Stereotactic body radiotherapy for unresectable cholangiocarcinoma Radiother Oncol 94 2010 47 52
9. P. Baumann, J. Nyman, and M. Hoyer Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study Radiother Oncol 88 2008 359 367
10. Z. Fuks, and R. Kolesnick Engaging the vascular component of the tumor response Cancer Cell 8 2005 89 91
11. M.T. Milano, A.W. Katz, and A.G. Muhs A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions Cancer 112 2008 650 658
12. S. Hapani, D. Chu, and S. Wu Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol 10 2009 559 568
13. M. Walraven, P.O. Witteveen, and M.P. Lolkema Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review Angiogenesis 14 2011 135 141
14. M. Hoyer, H. Roed, and A. Traberg Hansen Phase II study on stereotactic body radiotherapy of colorectal metastases Acta Oncol 45 2006 823 830
15. J.D. Murphy, C. Christman-Skieller, and J. Kim A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer Int J Radiat Oncol Biol Phys 78 2010 1420 1426
16. B.M. Barney, K.R. Olivier, and O.K. Macdonald Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors Am J Clin Oncol 35 2012 537 542
17. C. Park, L. Papiez, and S. Zhang Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy Int J Radiat Oncol Biol Phys 70 2008 847 852
18. B.G. Douglas, and J.F. Fowler The effect of multiple small doses of x-rays on skin reactions in the mouse and a basic interpretation Radiat Res 66 1976 401 426
19. E. Hedrick, M. Kozloff, and J. Hainsworth Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) [abstract] J Clin Oncol 24 Suppl. 2006 3536
20. M. Sugrue, M. Kozloff, and J. Hainsworth Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy [abstract] J Clin Oncol 24 Suppl. 2006 3535
21. H.S. Nimeiri, A.M. Oza, and R.J. Morgan Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia Gynecol Oncol 110 2008 49 55
22. J.L. Tanyi, G. McCann, and A.R. Hagemann Clinical predictors of bevacizumab-associated gastrointestinal perforation Gynecol Oncol 120 2011 464 469
23. C. Eveno, C. le Maignan, and P. Soyer Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication Clin Res Hepatol Gastroenterol 35 2011 135 139
24. N.A. Peters, D.J. Richel, and J.J. Verhoeff Bowel perforation after radiotherapy in a patient receiving sorafenib J Clin Oncol 26 2008 2405 2406
25. L.A. Dawson, A.M. Brade, and C. Cho Phase I study of sorafenib and SBRT for advanced hepatocellular carcinoma [abstract] Int J Radiat Oncol Biol Phys 84 Suppl. 2012 10 11
26. A.M. Brade, J. Kim, and J. Brierley Phase I study of sorafenib and whole-liver radiation therapy (WLRT) or stereotactic body radiation therapy (SBRT) for liver metastases [abstract] Int J Radiat Oncol Biol Phys 84 Suppl. 2012 11 12
27. Randomized phase III study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma. Available at: http://clinicaltrials.gov/ct2/show/NCT01730937. Accessed on April 24, 2013.
28. B.D. Kavanagh, C.C. Pan, and L.A. Dawson Radiation dose-volume effects in the stomach and small bowel Int J Radiat Oncol Biol Phys 76 Suppl. 2010 101 107
29. J.M. Roodhart, M.H. Langenberg, and E. Witteveen The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway Curr Clin Pharmacol 3 2008 132 143
30. J. Tol, A. Cats, and L. Mol Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation Invest New Drugs 26 2008 393 397
31. O. Mir, L. Mouthon, and J. Alexandre Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 99 2007 85 86
32. C.H. Crane, C. Eng, and B.W. Feig Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer Int J Radiat Oncol Biol Phys 76 2010 824 830
33. M.I. Koukourakis, A. Giatromanolaki, and P. Tsoutsou Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a phase II study Int J Radiat Oncol Biol Phys 80 2011 492 498
34. W. Small Jr., M.F. Mulcahy, and A. Rademaker Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer Int J Radiat Oncol Biol Phys 80 2011 476 482
35. C.G. Willett, D.G. Duda, and E. di Tomaso Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study J Clin Oncol 27 2009 3020 3026
36. C.H. Crane, L.M. Ellis, and J.L. Abbruzzese Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer J Clin Oncol 24 2006 1145 1151
37. F. Lordick, H. Geinitz, and J. Theisen Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases Int J Radiat Oncol Biol Phys 64 2006 1295 1298
38. M. Garcia-Barros, F. Paris, and C. Cordon-Cardo Tumor response to radiotherapy regulated by endothelial cell apoptosis Science 300 2003 1155 1159